OSR Health (OSRHW) Income from Non-Controlling Interests (2025 - 2026)
OSR Health (OSRHW) posted Income from Non-Controlling Interests of -$1.5 million for Q1 2026, down 266.31% sequentially from -$420470.0 in Q4 2025.
OSR Health (OSRHW) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends
OSR Health has reported Income from Non-Controlling Interests for 2 years, with the latest figure at -$1.5 million in Q1 2026.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.3 million (changed N/A YoY) and the FY2025 annual result came in at -$7.0 million, changed N/A from the prior year.
- Income from Non-Controlling Interests eased to -$1.5 million in Q1 2026 per OSRHW's latest filing, from -$420470.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$420470.0 in Q4 2025 and troughed at -$5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.12 Bn | 131.27 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.30 Bn | 77.31 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 62.84 Bn | 57.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.67 Bn | 50.53 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.43 Bn | 36.33 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.47 Bn | 9.08 Bn | 668.28 Mn | - |
| 8 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.03 Bn | 25.87 Bn | 358.27 Mn | - |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | -2.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.54 Mn |
| Dec 31, 2025 | -420,470.00 |
| Sep 30, 2025 | -1.82 Mn |
| Jun 30, 2025 | -5.56 Mn |